Collaboration

Bispecific antibodies
#Alentis Therapeutics #Antibody drug conjugate (ADC) #Biotechnology #Collaboration #Financing #Novo Holdings #Solid tumours

Successful collaboration to advance ADCs for solid tumours 

Novo Holdings has co-led a $181.4 million Series D financing in Alentis Therapeutics, a clinical-stage biotechnology company, headquartered in Basel, Switzerland, which is developing a pipeline of Claudin-1 (CLDN1) targeted medicines.  This financing will enable Alentis to begin Phase I/II trials for two first-in-class ADCs: ALE.P02, which targets advanced or… Read More

#Business & Investment #News

#Business #Collaboration #Drug discovery #Mergers and acquisitions #Partnership

Drug discovery companies partner to overcome challenges

The latest collaborations within drug discovery will focus on drug combinations, antibodies, nanovesicles, and organ-on-a-chip technology to advance the treatment of sarcopenia, and cardiovascular, kidney and genetic diseases. IsomAb and Catalent Biotechnology company IsomAb and Catalent have entered a strategic collaboration, which includes development of ISM-001 from cell line development… Read More

#Business & Investment #News

Antibodies
#Antiverse #Artificial intelligence (AI) #Collaboration #GPCRs #Nxera Pharma #Therapeutic Antibodies

Partners set out to design GPCR-targeted antibodies using AI

A new multi-target partnership aims meet unmet need by designing antibodies for G-protein coupled receptors (GPCRs). The collaboration will combine Antiverse’s generative AI antibody design expertise, including its proprietary machine-learning-generated ‘epitope-specific libraries’, with Nxera’s NxWave platform for GPCR target selection, validation and structural determination. The partnership hopes to bring transformative… Read More

#Business & Investment #News

Degeneration of dopaminergic neuron in Parkinson's disease
#Collaboration #Parkinson's #SandboxAQ #The Michael J Fox Foundation for Parkinson’s Research (MJFF) #University of Dundee

Partners launch $25m initiative to develop Parkinson’s treatments

SandboxAQ is collaborating with the University of Dundee in the UK to improve its inhibitor for the gene most commonly associated with Parkinson's disease (PD). The company has signed a $25 million research grant through The Michael J Fox Foundation for Parkinson's Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) programme. Read More

#Business & Investment #News

#Collaboration #Immunology #License agreement #Monte Rosa Therapeutics #Novartis

Novartis and Monte Rosa partner on molecular glue degraders

Monte Rosa Therapeutics and Novartis have agreed a global license agreement to advance VAV1 molecular glue degrader-based medicines (MGDs). The deal includes MRT-6160, which is currently in an ongoing Phase I study for immune-mediated conditions. Under the terms of the agreement, Novartis will obtain exclusive worldwide rights to develop, manufacture… Read More

#Business & Investment #News

#AAV #Collaboration #Dyno Therapeutics #Gene therapy #Neurology #Roche

Roche and Dyno advance AAV gene therapies for neurological diseases

Dyno Therapeutics and Roche have announced a second research collaboration to develop adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. Dyno and Roche previously agreed a research collaboration and license agreement for neurological diseases and liver-directed therapies in October 2020. Under the terms of this new collaboration, Dyno… Read More

#Business & Investment #News

AI concept
#Artificial intelligence (AI) #Collaboration #Financing #Generative AI #Machine learning

AI-powered drug discovery continues to attract investment

Optimism around the potential role for artificial intelligence (AI) in drug discovery continues, with recent financial deals supporting its use in developing therapeutics for age-related diseases, GPCR-targeting antibodies, DUB-modulating compounds, and novel fusion proteins. AI simulation to advance therapeutics for age-related diseases Biotech Shift Bioscience has raised $16 (£12.5) million… Read More

#Business & Investment #News

#Artificial intelligence (AI) #Automation / robotics #Collaboration #CRISPR #Partnership

Drug discovery companies partner on CRISPR, AI and automation

Several recent drug discovery partnerships have been announced that reflect the importance of new technologies and techniques to the efficient development of new therapeutics. ERS Genomics and Université de Montréal ERS Genomics and Université de Montréal (UdeM) have announced an agreement that grants the university access to ERS’ CRISPR/Cas9 patent… Read More

#Business & Investment #News

Gene therapy
#Asklepios BioPharmaceutical #Bayer #Belief BioMed #Collaboration #Gene therapy

AskBio and Belief BioMed explore potential new gene therapies

Bayer AG and Asklepios BioPharmaceutical (AskBio) have announced a new strategic collaboration with Belief BioMed (BBM) to explore the potential for new gene therapies. Under the terms of the contract, the companies will combine efforts and experience in gene therapy technology to explore potential therapies in diseases that may be… Read More

#Business & Investment #News

#Automata #Automation #Collaboration #Jan and Dan Duncan Neurological Research Institute (Duncan NRI) #Neuroscience #Texas Children's Hospital

Industry/research collaboration to automate human brain studies 

The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children’s Hospital, a neuroscience research institute based in Houston, has advanced its research capabilities with the implementation of an automation platform for human cellular model generation, maintenance, and characterisation, in collaboration with Automata Technologies.   As a global leader… Read More

#Business & Investment #News

Research in genetics laboratory
#Collaboration #Eli Lilly #Genetics / genomics #HAYA Therapeutics #Obesity

Lilly and HAYA collaborate to find genome targets for obesity

Eli Lilly and biotechnology company HAYA Therapeutics have announced a multi-year agreement to apply HAYA’s RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. The partners aim to identify multiple regulatory genome derived RNA-based drug targets to address these chronic conditions. Under the… Read More

#Business & Investment #News

CRISPR gene editing
#Collaboration #CRISPR-Cas9 #ERS Genomics #Genomics #Medicines Discovery Catapult (MDC)

ERS Genomics and MDC sign CRISPR/Cas9 license agreement

ERS Genomics and not-for-profit Medicines Discovery Catapult (MDC) have signed a non-exclusive commercial-use CRISPR license agreement. The partnership hopes to combine ERS’s CRISPR/Cas9 patent portfolio with MDC’s expertise and technology. As part of the deal, MDC and its partners will benefit from access to ERS’ CRISPR/Cas9 portfolio – the foundational… Read More

#Business & Investment #News

#Cardiovascular disease #Collaboration #Drug discovery #Flagship Pioneering #Partnership #Pfizer

Flagship and Quotient partner on cardiovascular disease therapies

Pfizer has expanded its strategic partnership with Flagship Pioneering, adding two new research programmes with Flagship-founded Quotient Therapeutics. Under the collaboration, the companies will analyse somatic mutations that occur in diseased patient tissue to inform the discovery and development of therapies for cardiovascular and renal diseases. Jacob Rubens, Co-Founder and… Read More

#Business & Investment #News

CAR-T therapy
#CAR-T #Caring Cross #Cell and gene therapy #Collaboration #GermFree #Manufacturing

Collaboration plans to democratise cell and gene therapies

Modular cleanroom company GermFree and non-profit Caring Cross have announced a new partnership, hoping to make cellular gene therapies more available to patients. The companies plan to create a decentralised, point-of-care manufacturing model that combines GermFree’s mobile cleanroom units with Caring Cross’s manufacturing technologies and pipeline… Read More

#News

#Absci #Artificial intelligence (AI) #Collaboration #Generative AI #Oncology #The Memorial Sloan Kettering Cancer Center

Partners use generative AI to develop novel cancer therapeutics

The Memorial Sloan Kettering Cancer Center (MSK) will be collaborating with Absci Corporation to discover and develop novel cancer therapeutics using generative artificial intelligence (AI) for up to six programmes. Under the terms of the collaboration, Absci and MSK’s cancer research teams will co-develop therapeutics using… Read More

#Cancer Research #News

Handshake jigsaw puzzle
#AI / data analytics / healthtech / informatics #Collaboration #Lab space #Lab technology #Partnership #Sapio Sciences #Zifo

Industry players partner to provide lab informatics  

Sapio Sciences and Zifo have announced a strategic partnership to bring best-in-class laboratory information management solutions to customers across the biotech, clinical diagnostics, and pharmaceutical industries.  Zifo will join the Sapio Sciences Partner Program as a services partner, focusing on delivering solutions that combine Zifo’s IT services… Read More

#News